

GENOMMA LAB ANNOUNCES FAVORABLE RESOLUTION FROM "COFECE" TO SELL MAJORITY STAKE OF GRUPO MARZAM



Mexico City, August 25, 2015

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company") announces that Mexico's *Comisión Federal de Competencia Económica (COFECE)* gave favorable resolution for the sale of 50% plus one share of Grupo Comercial e Industrial Marzam, S.A.P.I. de C.V. ("Grupo Marzam"), to Netherlands-based private equity firm Moench Coöperatief U.A.

According to the negotiated agreements, Genomma Lab will receive \$1.05 billion pesos at the end of September 2015 and the remaining \$300 million pesos one year after. The first payment will be primarily used to reduce financial debt of the Company.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low - cost, highly flexible supply chain operating model.

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Investor Relations
Tel: +52 (55) 5081 0000 Ext. 5106
E-mail: inversion@genommalab.com

In New York: Grayling USA, Lucía Domville
Tel: +1 (646) 284-9416
E-mail: genommalab@grayling.com